Why do hypertensive patients of African ancestry respond better to calciumblockers and diuretics than to ACE inhibitors and β-adrenergic blockers? Asystematic review
Open Access
- 30 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 11 (1), 141-16
- https://doi.org/10.1186/1741-7015-11-141
Abstract
Clinicians are encouraged to take an individualized approach when treatinghypertension in patients of African ancestry, but little is known about whythe individual patient may respond well to calcium blockers and diuretics,but generally has an attenuated response to drugs inhibiting therenin-angiotensin system and to β-adrenergic blockers. Therefore, wesystematically reviewed the factors associated with the differential drugresponse of patients of African ancestry to antihypertensive drugtherapy. Using the methodology of the systematic reviews narrative synthesis approach,we sought for published or unpublished studies that could explain thedifferential clinical efficacy of antihypertensive drugs in patients ofAfrican ancestry. PUBMED, EMBASE, LILACS, African Index Medicus and the Foodand Drug Administration and European Medicines Agency databases weresearched without language restriction from their inception through June2012. We retrieved 3,763 papers, and included 72 reports that mainly considered the4 major classes of antihypertensive drugs, calcium blockers, diuretics,drugs that interfere with the renin-angiotensin system and β-adrenergicblockers. Pharmacokinetics, plasma renin and genetic polymorphisms did notwell predict the response of patients of African ancestry toantihypertensive drugs. An emerging view that low nitric oxide and highcreatine kinase may explain individual responses to antihypertensive drugsunites previous observations, but currently clinical data are verylimited. Available data are inconclusive regarding why patients of African ancestrydisplay the typical response to antihypertensive drugs. In lieu ofbiochemical or pharmacogenomic parameters, self-defined African ancestryseems the best available predictor of individual responses toantihypertensive drugs.Keywords
This publication has 104 references indexed in Scilit:
- Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patientsPharmacogenetics and Genomics, 2011
- Plasma Renin Activity Predicts Blood Pressure Responses to -Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for HypertensionAmerican Journal of Hypertension, 2010
- Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazidePharmacogenetics and Genomics, 2010
- CYP3A4 and CYP3A5 Polymorphisms and Blood Pressure Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal DiseaseAmerican Journal of Nephrology, 2009
- Activation by Ca2+/calmodulin of an exogenous myosin light chain kinase in mouse arteriesThe Journal of Physiology, 2009
- G-Protein-Coupled Receptor Kinase 4 Polymorphisms and Blood Pressure Response to Metoprolol Among African Americans: Sex-Specificity and InteractionsAmerican Journal of Hypertension, 2009
- Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockadePharmacogenetics and Genomics, 2008
- Ethnic Differences in Cardiovascular Drug ResponseCirculation, 2008
- Genomic Association Analysis Suggests Chromosome 12 Locus Influencing Antihypertensive Response to Thiazide DiureticHypertension, 2008
- Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trialJournal Of Hypertension, 2007